Detalles de la búsqueda
1.
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
Rheumatology (Oxford)
; 62(2): 606-616, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35766811
2.
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet
; 395(10230): 1126-1136, 2020 04 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32178766
3.
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet
; 395(10230): 1115-1125, 2020 04 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32178765
4.
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.
Rheumatology (Oxford)
; 60(11): 5337-5350, 2021 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33822898
5.
A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma.
Ann Allergy Asthma Immunol
; 121(5): 568-574, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30102965
6.
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Drug Saf
; 47(1): 39-57, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37906417
7.
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
RMD Open
; 10(1)2024 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38531621
8.
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.
Clin Rheumatol
; 43(5): 1591-1604, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38472528
9.
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study.
BMC Rheumatol
; 8(1): 6, 2024 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38310261
10.
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis.
Rheumatol Ther
; 11(2): 425-441, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38386178
11.
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
Arthritis Rheumatol
; 76(6): 894-904, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38253404
12.
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
Trials
; 24(1): 22, 2023 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36627711
13.
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
RMD Open
; 9(1)2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36828643
14.
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.
ACR Open Rheumatol
; 5(3): 149-164, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36762512
15.
Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials.
ACR Open Rheumatol
; 5(9): 490-498, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37553909
16.
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis.
J Rheumatol
; 50(6): 769-780, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36642439
17.
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study.
Rheumatol Ther
; 10(6): 1637-1653, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37819505
18.
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies.
ACR Open Rheumatol
; 5(4): 227-240, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36880890
19.
Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.
Patient
; 15(6): 657-668, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35768650
20.
Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2).
Rheumatol Ther
; 9(4): 1017-1030, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35352313